Status:
COMPLETED
EHR-embedded OCDT in Breast or GI Cancer
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Oral Cancer Directed Therapy
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help resea...
Detailed Description
For patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy. * Participants will complete ePRO clinic for all medical oncology scheduled provider appointments...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult age 18 or older
- Male or Female
- Scheduled visit at DF/HCC within the BOC or GCC
- Diagnosis of advanced breast cancer or gastrointestinal cancer
- Prescribed any OCDT within prior 5 days of screening
- English as the primary language (as documented in the EHR, written or spoken, and patient interpreter needed flag = no)
- Mobile number listed in EHR to allow participation in ePP portion of the study
- Women of any pregnancy status
- Patients diagnosed with an advanced cancer will be eligible to participate in the study until discontinuation of OCDT or death, whichever occurs first
- Exclusion Criteria
- Adults unable to provide verbal consent
- Pediatric patients
- Patients without access to a electronic device (including tablet, computer, aptop or smartphone)
Exclusion
Key Trial Info
Start Date :
March 13 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 23 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03858712
Start Date
March 13 2019
End Date
November 23 2021
Last Update
May 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115